Daniel J O Roche1, Constantine J Trela2, Maria Argos3, Farzana Jasmine3,4, Muhammad G Kibriya3, Habibul Ahsan3, Andrea C King5. 1. Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA. 2. Department of Psychological Sciences, University of Missouri, 210 McAlester Hall, Columbia, MO 65211, USA. 3. Division of Epidemiology and Biostatistics, University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA. 4. Department of Public Health Studies, University of Chicago, Chicago, IL 60637, USA. 5. Department of Psychiatry and Behavioral Sciences, University of Chicago, Chicago, IL 60637, USA.
Abstract
AIMS: The present study examined how variation in mu- (OPRM1), kappa- (OPRK), and delta- (OPRD) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial. METHODS: The study's primary objective was to examine the association of the Asn40Asp OPRM1 single nucleotide polymorphism (SNP) with naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior during a double-blind, randomized clinical trial in 280 adult DSM-IV nicotine-dependent participants. The secondary goal of the study was to examine the relationship of 20 additional SNPs of OPRM1, OPRK, and OPRD with the aforementioned outcomes. RESULTS: Results indicated a null association between any opioid-receptor gene SNP and naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior in this sample of nicotine dependent participants. CONCLUSIONS: In sum, these results do not suggest that genetic variation in opioid-receptors is related to treatment responses to naltrexone in a smoking cessation trial.
AIMS: The present study examined how variation in mu- (OPRM1), kappa- (OPRK), and delta- (OPRD) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial. METHODS: The study's primary objective was to examine the association of the Asn40Asp OPRM1 single nucleotide polymorphism (SNP) with naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior during a double-blind, randomized clinical trial in 280 adult DSM-IV nicotine-dependent participants. The secondary goal of the study was to examine the relationship of 20 additional SNPs of OPRM1, OPRK, and OPRD with the aforementioned outcomes. RESULTS: Results indicated a null association between any opioid-receptor gene SNP and naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior in this sample of nicotine dependent participants. CONCLUSIONS: In sum, these results do not suggest that genetic variation in opioid-receptors is related to treatment responses to naltrexone in a smoking cessation trial.
Authors: Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch Journal: Int J Neuropsychopharmacol Date: 2008-09-17 Impact factor: 5.176
Authors: L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh Journal: NIDA Res Monogr Date: 1998-03
Authors: Jane E Sarginson; Joel D Killen; Laura C Lazzeroni; Stephen P Fortmann; Heather S Ryan; Alan F Schatzberg; Greer M Murphy Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2011-01-25 Impact factor: 3.568
Authors: Joel Gelernter; Ralitza Gueorguieva; Henry R Kranzler; Huiping Zhang; Joyce Cramer; Robert Rosenheck; John H Krystal Journal: Alcohol Clin Exp Res Date: 2007-04 Impact factor: 3.455
Authors: Elise M Weerts; Yu Kyeong Kim; Gary S Wand; Robert F Dannals; Jae Sung Lee; J James Frost; Mary E McCaul Journal: Neuropsychopharmacology Date: 2007-05-09 Impact factor: 7.853
Authors: S Khadka; B Narayanan; S A Meda; J Gelernter; S Han; B Sawyer; F Aslanzadeh; M C Stevens; K A Hawkins; A Anticevic; M N Potenza; G D Pearlson Journal: Transl Psychiatry Date: 2014-09-30 Impact factor: 6.222